SLC39A11 and invasive breast carcinoma: In terms of loss of function or decrease expression of the ZIP11 gene esophageal cancer patients represent the most affected population (8% of the patients), while for gain of function or increased expression of ZIP11, impacts primarily ovarian cysteous adenocarcinoma (almost 30% of the patients), followed by breast invasive carcinoma (approximately 22% of the individual; Supplementary Figure S1B).